arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Pulmonx Corp

LUNG
$2.00 ▼ -0.06 (-2.91%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
32 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pulmonx Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $84.9M
Dividend Yield
Revenue Growth -4.6%
Op. Margin -39.8%
ROIC -12.0%
FCF / Share $-0.12
Trailing P/E
Price / Book 2.2x
FCF Yield
Debt / Equity 0.96
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.76M
↓ -4.6%
Net Income Profit after all expenses
$-13.65M
↑ +5.5%
Operating Margin Operating profit as % of sales
-39.8%
↑ +36.8% 4th
FCF / Share Free cash flow per share
$-0.12
↑ +49.1%
Long-Term Debt Long-term obligations
$37.53M
↑ +0.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
9
Financial Health
33
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters